FDA advisory panel gives the thumbs up to J&J’s vaccine

Johnson & Johnson’s COVID-19 vaccine is one step closer to distribution. A panel of expert advisers gave the thumbs up to Johnson & Johnson’s COVID-19 vaccine Friday.

That recommendation then goes to the U.S. Food & Drug Administration, which is likely to grant authorization for its emergency use within a day or so, setting the stage for a planned rollout of three to four million doses next week. That would make J&J’s vaccine the third one available in the U.S. after those made by Pfizer/BioNTech and Moderna, and it would be the only one that requires just one shot.

Unlike the other two, J&J’s vaccine can be stored in normal refrigerator temperatures instead of ultra-cold storage. That makes distribution a lot easier.

A trial found that J&J’s vaccine was 66% effective at preventing moderate-to-severe cases of COVID-19. And it was 100% effective at preventing hospitalizations 28 days after vaccination.

Video Transcript

- Johnson & Johnson's COVID-19 vaccine is one step closer to distribution. A panel of expert advisors gave the thumbs up to J&J's COVID-19 vaccine on Friday. That recommendation then goes to the US Food and Drug Administration, which is likely to grant authorization for its emergency use within a day or so, setting the stage for a planned rollout of three to four million doses next week. That would make J&J's vaccine the third one available in the US after those made by Pfizer, BioNTech, and Moderna. And it would be the only one that requires just one shot.

Unlike the other two, J&J's vaccine can be stored in normal refrigerator temperatures instead of ultra-cold storage. That makes distribution a lot easier. A trial found that J&J's vaccine was 66% effective at preventing moderate to severe cases of COVID-19, and it was 100% effective at preventing hospitalizations 28 days after vaccination.